Biblio
“The Impact of APOE ɛ4 in Alzheimer's Disease Differs According to Age.”, J Alzheimers Dis, vol. 61, no. 4, pp. 1377-1385, 2018.
, “Cognitive Impairment Is a Common Comorbidity in Deceased COVID-19 Patients: A Hospital-Based Retrospective Cohort Study.”, J Alzheimers Dis, vol. 78, no. 4, pp. 1367-1372, 2020.
, “Death Rate Due to COVID-19 in Alzheimer's Disease and Frontotemporal Dementia.”, J Alzheimers Dis, vol. 78, no. 2, pp. 537-541, 2020.
, “Age and its association with low insulin and high amyloid-β peptides in blood.”, J Alzheimers Dis, vol. 49, no. 1, pp. 129-37, 2016.
, “Association of Low-Level Ozone with Cognitive Decline in Older Adults.”, J Alzheimers Dis, vol. 61, no. 1, pp. 67-78, 2018.
, “Genetic Influences on Plasma Homocysteine Levels in African Americans and Yoruba Nigerians.”, J Alzheimers Dis, vol. 49, no. 4, pp. 991-1003, 2016.
, “A Meta-Analysis of Alzheimer's Disease Incidence and Prevalence Comparing African-Americans and Caucasians.”, J Alzheimers Dis, vol. 50, no. 1, pp. 71-6, 2016.
, “The Role of Ethnicity in Alzheimer's Disease: Findings From The C-PATH Online Data Repository.”, J Alzheimers Dis, vol. 51, no. 2, pp. 515-23, 2016.
, “Genetic Influences on Plasma Homocysteine Levels in African Americans and Yoruba Nigerians.”, J Alzheimers Dis, vol. 49, no. 4, pp. 991-1003, 2016.
, “Rationale and Design of the Mechanistic Potential of Antihypertensives in Preclinical Alzheimer's (HEART) Trial.”, J Alzheimers Dis, vol. 61, no. 2, pp. 815-824, 2018.
, “Plasma Biomarkers of Alzheimer's Disease in African Americans.”, J Alzheimers Dis, vol. 79, no. 1, pp. 323-334, 2021.
, “A Comparison of Behavioral and Psychological Symptoms of Dementia (BPSD) and BPSD Sub-Syndromes in Early-Onset and Late-Onset Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 691-699, 2022.
, “Pain Assessment in Elderly with Behavioral and Psychological Symptoms of Dementia.”, J Alzheimers Dis, vol. 50, no. 4, pp. 1217-25, 2016.
, “Comparing the Effects of Multisensory Stimulation and Individualized Music Sessions on Elderly People with Severe Dementia: A Randomized Controlled Trial.”, J Alzheimers Dis, vol. 52, no. 1, pp. 303-15, 2016.
, “Report of the task force on designing clinical trials in early (predementia) AD.”, Neurology, vol. 76, no. 3, pp. 280-6, 2011.
, “Early Life Stress Enhances Cognitive Decline and Alters Synapse Function and Interneuron Numbers in Young Male APP/PS1 Mice.”, J Alzheimers Dis, vol. 96, no. 3, pp. 1097-1113, 2023.
, “How Do Persons with Young and Late Onset Dementia Die?”, J Alzheimers Dis, vol. 81, no. 2, pp. 843-852, 2021.
, “Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years.”, J Neuropathol Exp Neurol, vol. 70, no. 11, pp. 960-9, 2011.
, “Human apoE isoforms differentially regulate brain amyloid-β peptide clearance.”, Sci Transl Med, vol. 3, no. 89, p. 89ra57, 2011.
, “Predictive Value of Cerebrospinal Fluid Visinin-Like Protein-1 Levels for Alzheimer's Disease Early Detection and Differential Diagnosis in Patients with Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 50, no. 3, pp. 765-78, 2016.
, “Posterior Accumulation of Tau and Concordant Hypometabolism in an Early-Onset Alzheimer's Disease Patient with Presenilin-1 Mutation.”, J Alzheimers Dis, vol. 51, no. 2, pp. 339-43, 2016.
, “Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies.”, Ann Neurol, vol. 73, no. 4, pp. 449-58, 2013.
, “Predictive factors for disease progression in patients with early-onset Alzheimer's disease.”, J Alzheimers Dis, vol. 49, no. 1, pp. 85-91, 2016.
, “Clinical Impact of a Second FDG-PET in Atypical/Unclear Dementia Syndromes.”, J Alzheimers Dis, vol. 49, no. 3, pp. 695-705, 2016.
, “The Incidence of Benzodiazepine and Related Drug Use in Persons with and without Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 3, pp. 809-18, 2016.
,